308 related articles for article (PubMed ID: 32006430)
1. Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines Against Influenza B in the United States, 2011-2012 to 2016-2017.
Gaglani M; Vasudevan A; Raiyani C; Murthy K; Chen W; Reis M; Belongia EA; McLean HQ; Jackson ML; Jackson LA; Zimmerman RK; Nowalk MP; Monto AS; Martin ET; Chung JR; Spencer S; Fry AM; Flannery B
Clin Infect Dis; 2021 Apr; 72(7):1147-1157. PubMed ID: 32006430
[TBL] [Abstract][Full Text] [Related]
2. Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017-2018 and 2018-2019 Influenza Seasons.
Boikos C; Fischer L; O'Brien D; Vasey J; Sylvester GC; Mansi JA
Clin Infect Dis; 2021 Sep; 73(5):816-823. PubMed ID: 33605977
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
Treanor JT; Albano FR; Sawlwin DC; Graves Jones A; Airey J; Formica N; Matassa V; Leong J
Vaccine; 2017 Apr; 35(15):1856-1864. PubMed ID: 28302411
[TBL] [Abstract][Full Text] [Related]
4. Assessment of potential public health impact of a quadrivalent inactivated influenza vaccine in Thailand.
Kittikraisak W; Chittaganpitch M; Gregory CJ; Laosiritaworn Y; Thantithaveewat T; Dawood FS; Lindblade KA
Influenza Other Respir Viruses; 2016 May; 10(3):211-9. PubMed ID: 26588892
[TBL] [Abstract][Full Text] [Related]
5. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season.
Grohskopf LA; Sokolow LZ; Broder KR; Walter EB; Bresee JS; Fry AM; Jernigan DB
MMWR Recomm Rep; 2017 Aug; 66(2):1-20. PubMed ID: 28841201
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States.
Clements KM; Meier G; McGarry LJ; Pruttivarasin N; Misurski DA
Hum Vaccin Immunother; 2014; 10(5):1171-80. PubMed ID: 24609063
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach.
Brogan AJ; Talbird SE; Davis AE; Thommes EW; Meier G
Hum Vaccin Immunother; 2017 Mar; 13(3):533-542. PubMed ID: 27780425
[TBL] [Abstract][Full Text] [Related]
8. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
Sesay S; Brzostek J; Meyer I; Donazzolo Y; Leroux-Roels G; Rouzier R; Astruc B; Szymanski H; Toursarkissian N; Vandermeulen C; Kowalska E; Van Damme P; Salamand C; Pepin S
Hum Vaccin Immunother; 2018 Mar; 14(3):596-608. PubMed ID: 28968138
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults.
Gorse GJ; Falsey AR; Ozol-Godfrey A; Landolfi V; Tsang PH
Vaccine; 2015 Feb; 33(9):1151-9. PubMed ID: 25613721
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
[TBL] [Abstract][Full Text] [Related]
11. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
[TBL] [Abstract][Full Text] [Related]
12. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season.
Grohskopf LA; Sokolow LZ; Broder KR; Walter EB; Fry AM; Jernigan DB
MMWR Recomm Rep; 2018 Aug; 67(3):1-20. PubMed ID: 30141464
[TBL] [Abstract][Full Text] [Related]
13. An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model.
Chit A; Roiz J; Aballea S
PLoS One; 2015; 10(7):e0133606. PubMed ID: 26222538
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults.
Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Wateska A; France GS; Zimmerman RK
Vaccine; 2017 Oct; 35(42):5708-5713. PubMed ID: 28890196
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres.
Pepin S; Dupuy M; Borja-Tabora CFC; Montellano M; Bravo L; Santos J; de Castro JA; Rivera-Medina DM; Cutland C; Ariza M; Diez-Domingo J; Gonzalez CD; Martinón-Torres F; Papadopoulou-Alataki E; Theodoriadou M; Kazek-Duret MP; Gurunathan S; De Bruijn I;
Vaccine; 2019 Mar; 37(13):1876-1884. PubMed ID: 30558818
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
Greenberg DP; Robertson CA; Talbot HK; Decker MD
Hum Vaccin Immunother; 2017 Sep; 13(9):2058-2064. PubMed ID: 28700265
[TBL] [Abstract][Full Text] [Related]
17. Comparisons in the Health and Economic Assessments of Using Quadrivalent Versus Trivalent Influenza Vaccines: A Systematic Literature Review.
Warmath CR; Ortega-Sanchez IR; Duca LM; Porter RM; Usher MG; Bresee JS; Lafond KE; Davis WW
Value Health; 2023 May; 26(5):768-779. PubMed ID: 36436790
[TBL] [Abstract][Full Text] [Related]
18. Enhanced passive safety surveillance of a trivalent and a quadrivalent influenza vaccine in Denmark and Finland during the 2018/2019 season.
Serradell L; Wagué S; Moureau A; Nissilä M; Chabanon AL
Hum Vaccin Immunother; 2021 Apr; 17(4):1205-1210. PubMed ID: 32966139
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults.
Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Zimmerman RK
J Am Geriatr Soc; 2016 Oct; 64(10):2126-2131. PubMed ID: 27709600
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of Influenza Vaccines Among US Medicare Beneficiaries Ages 65 Years and Older During the 2019-2020 Season.
Izurieta HS; Lu M; Kelman J; Lu Y; Lindaas A; Loc J; Pratt D; Wei Y; Chillarige Y; Wernecke M; MaCurdy TE; Forshee R
Clin Infect Dis; 2021 Dec; 73(11):e4251-e4259. PubMed ID: 33211809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
